AC Immune (NASDAQ:ACIU) Shares Cross Below 50-Day Moving Average – Here’s What Happened

AC Immune (NASDAQ:ACIU)’s stock price crossed below its 50 day moving average during trading on Tuesday . The stock has a 50 day moving average of $3.00 and traded as low as $2.59. AC Immune shares last traded at $2.75, with a volume of 127,564 shares changing hands.

Analysts Set New Price Targets

ACIU has been the topic of a number of recent research reports. Wall Street Zen raised shares of AC Immune from a “sell” rating to a “hold” rating in a report on Saturday, February 28th. BTIG Research reaffirmed a “buy” rating and set a $8.00 target price on shares of AC Immune in a report on Monday, March 16th. Weiss Ratings reiterated a “sell (d-)” rating on shares of AC Immune in a research report on Wednesday, January 21st. Finally, Jefferies Financial Group reissued a “buy” rating and issued a $7.00 price target on shares of AC Immune in a report on Friday, March 13th. Three analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, AC Immune presently has an average rating of “Hold” and an average price target of $9.00.

AC Immune Stock Up 7.4%

The firm’s 50-day moving average price is $3.00 and its 200 day moving average price is $3.09. The firm has a market cap of $279.87 million, a P/E ratio of -3.27 and a beta of 1.64.

AC Immune (NASDAQ:ACIU) last issued its quarterly earnings data on Friday, March 13th. The company reported ($0.18) earnings per share for the quarter, beating the consensus estimate of ($0.19) by $0.01. The firm had revenue of $0.44 million for the quarter, compared to the consensus estimate of $1.14 million. AC Immune had a negative net margin of 1,977.71% and a negative return on equity of 103.15%. On average, equities analysts predict that AC Immune will post -0.62 earnings per share for the current year.

Institutional Investors Weigh In On AC Immune

A number of hedge funds have recently made changes to their positions in the business. Acadian Asset Management LLC grew its holdings in AC Immune by 87.1% in the 1st quarter. Acadian Asset Management LLC now owns 371,177 shares of the company’s stock worth $679,000 after buying an additional 172,796 shares in the last quarter. Sei Investments Co. bought a new stake in AC Immune during the 2nd quarter valued at $51,000. Assenagon Asset Management S.A. bought a new stake in AC Immune during the 3rd quarter valued at $549,000. Private Advisor Group LLC acquired a new position in AC Immune during the 3rd quarter worth $48,000. Finally, Susquehanna International Group LLP acquired a new position in AC Immune during the 3rd quarter worth $63,000. Institutional investors own 51.36% of the company’s stock.

AC Immune Company Profile

AC Immune AG is a clinical-stage biopharmaceutical company headquartered in Lausanne, Switzerland, with a subsidiary in Boston, Massachusetts. The company specializes in the discovery and development of therapeutics and diagnostics for neurodegenerative diseases, with a primary focus on Alzheimer’s disease, Parkinson’s disease and other protein misfolding disorders. AC Immune leverages proprietary platform technologies to identify and optimize candidates that target pathological protein aggregates.

Since its founding in 2003, AC Immune has advanced multiple programs into clinical development.